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Head and neck cancer
3D vs IMRT in head and neck cancer. Quality of life
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Purpose. Patients may achieve a better quality of life (QOL) after IMRT compared with conventional 3D Radiotherapy (RDT) for
head and neck cancer patients. The period of study was from 2005 to 2009.
Material and method. A retrospective study onQOL in patients treated for head and neck cancer and thosewhohave been subjected
to the standard questionnaire about their physical status andquality of life QLQ-H&N35. A total of 168 patients have been treated,
79 were treated with 3D Radiation (2005–2008) and 89 patients with integrated boost IMRT (2008–2009). 66 patients were evaluated
by the standard questionnaire about their physical status QLQ-H & N35 (22 with 3D and 44 with IMRT) speciﬁcally xerostomia
and chronic sequelae in the oral cavity area.
Results. 3D 60% of patients received postoperative RDT. Radical RDT 40%± chemotherapy. Tumor stage at diagnosis is 60% ≥T3
and 65% ≥N1; In N+ more frequently N2b. Patients were treated as follows: 4 for nasopharynx, 6 oropharynx, 10 relapses of
larynx, hypopharynx or oral cavity after surgery, 1 multifocal, 9 hypopharynx, 12 oral cavity, 20 supraglottic, 16 glottic and 1
subglottis. 22 patients were evaluated for chronic xerostomia (GII ≥50%, and 30% GI). Mean score QOL was 49 (37–97). IMRT 36%
of patients were treated with radical surgery followed by RDT or RDT-QT. For patients who did not undergo surgery, the most
common treatment was concomitant RDT-QT. 52% of cases ≥T3 tumor stage, nodal stage 72% ≥N1. In N+, 31%N1 and 20% N2b.
In regards to primary tumor, the cases seen were; 16 nasopharynx, 20 oropharynx, 2 relapses of larynx and 4 of oral cavity, 3
multicenter, 11 hypopharynx, 6 oral cavity, 16 supraglottic and 11 glottic. 41 patients were evaluated for chronic xerostomia (GII
≥36%, and 32% GI Mean score QOL was 40 (34-67)).
Conclusion. Patients treated with IMRT show a better quality of life compared to those treated with conventional radiation therapy,
reducing the appearance of more severe sequelae.
http://dx.doi.org/10.1016/j.rpor.2013.03.248
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Introduction. For years the use of induction chemotherapy (ICT) followed by external radiotherapy (ERT) with concomitant cetux-
imab was the standard of treatment in patients with locally advanced squamos cell carcinoma of the head and neck (SCCHN).
In selected patients, induction chemotherapy could facilitate organ perservation, avoid morbility surgery and improve quality of
life of the patient.
Purpose. To investigate the tolerance of ICT with docetaxel, cisplatin, and 5-Fluorouracil (TPF) followed by ERT with concomitant
cetuximab in the treatment of patients with SCCHN.
Patients and methods. This trial enrolled 28 eligible patients with Stage III or IV nonmetastatic oropharyngeal and hypopharyngeal
carcinoma who received ICT followed by ERT with concomitant cetuximab were retrospectively analyzed. Clinical safety (weight,
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allergy, mucositis, and radiodermatitis) and paraclinical safety (levels of hemoglobin, polynuclear neutrophils and platelets) were
studied.
Results. Induction chemotherapy was better tolerated than that previously reported. The suspension of radiation and hospitaliza-
tion was only observed in one patient (3.5%) during concomitant treatment. The mean dose of radiotherapy administrated over
the tumor bed was 70 Gy 96.5% of patients lost <10% of their body weigth. The incidence of severe hematological toxicity was very
low (9% grade III thrombocytopenia). Radiodermatitis grade I–II occurred in 64% of the patients. No grade III of radiodermatitis
was experienced. 43% of patients presented mucositis grade II, 7% grade III and no grade IV or above was observed. There were
no allergic reactions to cetuximab.
Conclusion. The completed protocol rate for oropharyngeal and hypopharyngeal patients receiving ICT and ERT with concomitant
cetuximab has an acceptable toxicity. Future improvements to protocol will be possible through early action and systematic
implementation of nutritional support coupled with antibiotic treatment upon the ﬁrst signs of radiodermatitis.
http://dx.doi.org/10.1016/j.rpor.2013.03.249
Adaptive radiotherapy based on functional images
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Introduction and objectives. Functional imaging techniques (PET/CT, MRI) allow us to associate treatment response to delivered
dose quantitatively. We are developing a research project (2012–2014) focused on the quantiﬁcation of tumor response by MRI
and PET/CT.
Material andmethods.We select patientswith locally advancedoropharyngeal tumors, stageT3andT4.All received IMRT treatment
(standard doses of 66Gy). The recording protocol is scheduled as follows: pre-treatment: MRI (1.5T Philips Achieva; single-shot
echo-planar diffusion-weighted MR sequence with different b-values) and PET/CT (PET/CT full body, 370MBq of 18F-FDG, GE
Discovery STE 16unit). First MRI (10–20Gy): diffusion, ADC map. Second MRI (20–50Gy): diffusion, ADC map. 3 Months after
treatment: PET/CT and MRI (diffusion and ADC map). The patients were standing with RT immobilization devices. Only low
distorted slices were analyzed. Were recorded for each patient ADC, SUV, and HU dose per voxel (3mm×3mm×3mm) of each
volume.
Results and discussion. The mean value for ADC and tumor nodules was 1.29×10−3 mm2/s can be set to a Gaussian curve with
a FWHM=0.73×10−3 mm2/s. Using as ﬁlters ADC±FWHM/2, and SUV>1 for the initial ADC and averaged for each volume is
obtained ADC increased with dose for both patients. We see an increase in ADC with increasing dose.
Conclusions. ADC maps can be used for quantifying voxel by voxel the tumor response. The dataset using MRI diffusion and
PET/CT may be useful to identify areas of hypoxia. We recommend the use of the both sets of images to contour the VOI. The
main weakness of this approach is the rigid registration process, so we need new non-rigid registration algorithms for highly
distorted images of diffusion studies. Supported by ISCIII Grant PI11/02035.
http://dx.doi.org/10.1016/j.rpor.2013.03.250
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Introduction. (1) Head and neck tumours synchronous with another tumor in different location are rare and have a poor prognosis
(2-year overall survival 0% if both advanced). (2) Nevertheless, a 33.9% 3-year overall survival has been achieved for selected
patients. (3) When a radiotherapy plan targeting both tumours could be required it is not always feasible since getting acceptable
PTV coverage, without violating OAR constraints, could be difﬁcult. Also, risk of under/overdosing in matching area exists.
Objective. To evaluate the effectiveness of MONACO planner for IMRT treatments in H&N and lung synchronous tumors.
Methods and materials. Two patients diagnosed of a synchronous H&N and lung tumors. Patient 1: base of the tongue cancer
(pTxpN2cM0) and right lower lobe cancer (cT2cN2M0), both squamous cell cancers. Patient 2: glottis squamous cell cancer
(cT4acN1M0) and right upper lobe adenocarcinoma (T3N2M0). Radiotherapy treatment: IMRT with inverse planning and bio-
logical function based optimization obtained with TPS Monaco (CMS/Elekta, Maryland Heights, MO). An static technique type
step and shoot has been employed, and a daily veriﬁcation (kilovoltage cone-beam CT) was performed. Thermoplastic shoulder
mask device+ silicone bite positioner for immobilization were used.
Results. H&N targets. PTV 66: average volumen 137/172 cc; D95>97.8%. PTV 60: average volume: 394.57cc; D95>96%. Parotid
glands: only in one V30>50% (53.6%). Remaining OAR fulﬁlled dose constraints. Lung targets. PTV (60+66): average volume
230.95 cc; D95>97.5%. Esopaghus: V35<46%. Lung: V20<31%.
Conclusions. (1) Biological function based planiﬁcation systems work in all points along the histogram curve obtaining a better
OAR preservation without decreasing excessive the PTV coverage in complex plans. (2) Monaco allows to use only one isocenter
